BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vitiello A, Pelliccia C, Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy.SN Compr Clin Med. 2020;1-4. [PMID: 32875276 DOI: 10.1007/s42399-020-00487-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Horlock D, Kaye DM, Winbanks CE, Gao XM, Kiriazis H, Donner DG, Gregorevic P, McMullen JR, Bernardo BC. Old Drug, New Trick: Tilorone, a Broad-Spectrum Antiviral Drug as a Potential Anti-Fibrotic Therapeutic for the Diseased Heart. Pharmaceuticals (Basel) 2021;14:263. [PMID: 33804032 DOI: 10.3390/ph14030263] [Reference Citation Analysis]
2 Abu-El-Rub E, Khasawneh RR, Almahasneh F, Altaany Z, Bataineh N, Zegallai H, Sekaran S. Mesenchymal stem cells and COVID-19: What they do and what they can do. World J Stem Cells 2021; 13(9): 1318-1337 [PMID: 34630865 DOI: 10.4252/wjsc.v13.i9.1318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gatti M, De Ponti F. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 2021;13:302. [PMID: 33668969 DOI: 10.3390/pharmaceutics13030302] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
4 Vitiello A, Ferrara F. Antidiabetes Agents against Sars-Cov-2 Infection. SN Compr Clin Med 2020;:1-4. [PMID: 33134845 DOI: 10.1007/s42399-020-00608-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Li Y, Peng Z, Holl NJ, Hassan MR, Pappas JM, Wei C, Izadi OH, Wang Y, Dong X, Wang C, Huang YW, Kim D, Wu C. MXene-Graphene Field-Effect Transistor Sensing of Influenza Virus and SARS-CoV-2. ACS Omega 2021;6:6643-53. [PMID: 33748577 DOI: 10.1021/acsomega.0c05421] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 33.0] [Reference Citation Analysis]
6 Martínez Redondo J, Comas Rodríguez C, Pujol Salud J, Crespo Pons M, García Serrano C, Ortega Bravo M, Palacín Peruga JM. Higher Accuracy of Lung Ultrasound over Chest X-ray for Early Diagnosis of COVID-19 Pneumonia. Int J Environ Res Public Health 2021;18:3481. [PMID: 33801638 DOI: 10.3390/ijerph18073481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kiener M, Roldan N, Machahua C, Sengupta A, Geiser T, Guenat OT, Funke-Chambour M, Hobi N, Kruithof-de Julio M. Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. Front Med (Lausanne) 2021;8:644678. [PMID: 34026781 DOI: 10.3389/fmed.2021.644678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Dreyer NA, Reynolds M, DeFilippo Mack C, Brinkley E, Petruski-Ivleva N, Hawaldar K, Toovey S, Morris J. Self-reported symptoms from exposure to Covid-19 provide support to clinical diagnosis, triage and prognosis: An exploratory analysis. Travel Med Infect Dis 2020;38:101909. [PMID: 33152512 DOI: 10.1016/j.tmaid.2020.101909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Altube MJ, Caimi LI, Huck-Iriart C, Morilla MJ, Romero EL. Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. Pharmaceutics 2021;13:1331. [PMID: 34575407 DOI: 10.3390/pharmaceutics13091331] [Reference Citation Analysis]
10 Mohammadi A, Balan I, Yadav S, Matos WF, Kharawala A, Gaddam M, Sarabia N, Koneru SC, Suddapalli SK, Marzban S. Post-COVID-19 Pulmonary Fibrosis. Cureus 2022;14:e22770. [PMID: 35371880 DOI: 10.7759/cureus.22770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 2020;262:118510. [PMID: 32991879 DOI: 10.1016/j.lfs.2020.118510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
12 Sgalla G, Comes A, Lerede M, Richeldi L. COVID-related fibrosis: insights into potential drug targets. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34842488 DOI: 10.1080/13543784.2021.2010188] [Reference Citation Analysis]
13 Lu ZH, Yang CL, Yang GG, Pan WX, Tian LG, Zheng JX, Lv S, Zhang SY, Zheng PY, Zhang SX. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial. Infect Dis Poverty 2021;10:31. [PMID: 33731163 DOI: 10.1186/s40249-021-00813-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mauad T, Duarte-Neto AN, da Silva LFF, de Oliveira EP, de Brito JM, do Nascimento ECT, de Almeida Monteiro RA, Ferreira JC, de Carvalho CRR, do Nascimento Saldiva PH, Dolhnikoff M. Tracking the time course of pathological patterns of lung injury in severe COVID-19. Respir Res 2021;22:32. [PMID: 33514373 DOI: 10.1186/s12931-021-01628-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
15 Li F, Wang G, Zhang W, Zhang C. Efficacy and safety of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis caused by novel coronavirus disease: A protocol for Bayesian network meta-analysis. Medicine (Baltimore) 2021;100:e28282. [PMID: 34941111 DOI: 10.1097/MD.0000000000028282] [Reference Citation Analysis]
16 Parisi GF, Carota G, Castruccio Castracani C, Spampinato M, Manti S, Papale M, Di Rosa M, Barbagallo I, Leonardi S. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature. Int J Mol Sci 2021;22:2465. [PMID: 33671104 DOI: 10.3390/ijms22052465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Vitiello A, Ferrara F. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 2021;38:S129-30. [PMID: 33687000 DOI: 10.4103/lungindia.lungindia_803_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]